Harvard Bioscience Files Two Major Patents In Field Of Regenerative Medicine
HOLLISTON, Mass., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ("Harvard Bioscience," or the "Company") (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth.
David Green, President of Harvard Bioscience, commented, "This is an important milestone for Harvard Bioscience illustrating the value we place on our intellectual property in the emerging field of regenerative medicine. Our strategy is to supply tools to researchers and clinicians within the field of regenerative medicine, and completing these patent filings marks an important milestone in that plan."
Harvard Bioscience is collaborating with leading academics in the field of regenerative medicine to develop its regenerative medicine products. In 2009, the Company licensed the bioreactor technology underlying the world's first human transplant of a regenerated bronchus. The transplant was performed by Dr. Paolo Macchiarini at the Department of General Thoracic Surgery, Hospital Clinic, Barcelona, Spain and the work was published in The Lancet on November 19, 2008. This "InBreath" bioreactor is now commercially available. In 2010, the Company's Harvard Apparatus / Hugo Sachs Elektronik business collaborated with Dr. Harald Ott and Massachusetts General Hospital to design and manufacture a novel bioreactor that was used to grow a functional lung that was transplanted into a rat. The research was published online in Nature Medicine on July 13, 2010.In addition to developing bioreactors, Harvard Bioscience is also developing a stem cell therapy injector based on its market leading Harvard Apparatus research syringe pump technology. The Company expects to submit this injector to the US FDA next year for approval for clinical use on patients.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV